A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of GDC-8264 in Preventing Cardiac Surgery-Associated Acute Kidney Injury and Major Adverse Kidney Events
Latest Information Update: 30 Sep 2024
At a glance
- Drugs RG 6287 (Primary)
- Indications Acute kidney injury
- Focus Adverse reactions; Therapeutic Use
- Sponsors Genentech
- 30 Sep 2024 New trial record